Annals of Surgical Oncology, Vol 6, Issue 8 719-726, Copyright © 1999 by Society of Surgical Oncology

ARTICLES

Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma

R. D. Schulick and M. F. Brennan
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.

BACKGROUND: One of the key issues in the treatment of adrenocortical carcinoma is the efficacy of repeat resection of local recurrence and metastatic disease in affected patients. Options in the treatment of locally recurrent or metastatic disease are limited because chemotherapy and radiotherapy generally do not provide any significant prolongation in survival in treated patients. METHODS: A series of 113 patients who presented to Memorial Sloan-Kettering Cancer Center for treatment of adrenocortical carcinoma are presented. RESULTS: The median overall survival for all 113 patients was 38 months (5-year survival, 37%). Patients presenting with early stage I or II disease (n = 57) had a median survival of 101 months (5-year survival, 60%), whereas those with late stage III or IV disease (n = 56) had a median survival of 15 months (5-year survival, 10%). Patients who had complete primary resection (n = 68) had a median survival of 74 months (5-year survival, 55%), whereas those with incomplete primary resection (n = 45) had a median survival of 12 months (5-year survival, 5%). Resection of locally recurrent or distant metastatic disease was performed in 47 of these patients. Patients who had a complete second resection had a median survival of 74 months (5-year survival, 57%), whereas those with incomplete second resection had a median survival of 16 months (5-year survival, 0%). CONCLUSIONS: Improved survival is seen in patients who present with early stage and have complete primary resection. Patients who undergo complete repeat resection of local recurrence or distant metastasis also have improved survival. Complete repeat resection was more readily accomplished in discrete distant metastatic lesions compared with bulky local recurrences.

This article has been cited by other articles:

				I G C Hermsen, H Gelderblom, J Kievit, J A Romijn, and H R Haak Extremely long survival in six patients despite recurrent and metastatic adrenal carcinoma. Eur. J. Endocrinol., June 1, 2008; 158(6): 911 - 919. [Abstract] [Full Text] [PDF]

				M. Terzolo, A. Angeli, M. Fassnacht, F. Daffara, L. Tauchmanova, P. A. Conton, R. Rossetto, L. Buci, P. Sperone, E. Grossrubatscher, et al. Adjuvant Mitotane Treatment for Adrenocortical Carcinoma N. Engl. J. Med., June 7, 2007; 356(23): 2372 - 2380. [Abstract] [Full Text] [PDF]

				S. Ohwada, M. Izumi, S. Kawate, K. Hamada, H. Toya, N. Togo, J. Horiguchi, Y. Koibuchi, T. Takahashi, and M. Yamada Surgical Outcome of Stage III and IV Adrenocortical Carcinoma Jpn. J. Clin. Oncol., February 2, 2007; (2007) hyl127v1. [Abstract] [Full Text] [PDF]

				G. Assie, G. Antoni, F. Tissier, B. Caillou, G. Abiven, C. Gicquel, S. Leboulleux, J.-P. Travagli, C. Dromain, X. Bertagna, et al. Prognostic Parameters of Metastatic Adrenocortical Carcinoma J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 148 - 154. [Abstract] [Full Text] [PDF]

				B. Allolio and M. Fassnacht Adrenocortical Carcinoma: Clinical Update J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2027 - 2037. [Abstract] [Full Text] [PDF]

				S. Leboulleux, C. Dromain, G. Bonniaud, A. Auperin, B. Caillou, J. Lumbroso, R. Sigal, E. Baudin, and M. Schlumberger Diagnostic and Prognostic Value of 18-Fluorodeoxyglucose Positron Emission Tomography in Adrenocortical Carcinoma: A Prospective Comparison with Computed Tomography J. Clin. Endocrinol. Metab., March 1, 2006; 91(3): 920 - 925. [Abstract] [Full Text] [PDF]

				A. Berruti, M. Terzolo, P. Sperone, A. Pia, S. Della Casa, D. J Gross, C. Carnaghi, P. Casali, F. Porpiglia, F. Mantero, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial Endocr. Relat. Cancer, September 1, 2005; 12(3): 657 - 666. [Abstract] [Full Text] [PDF]

				E. Baudin, C. Docao, C. Gicquel, G. Vassal, A. Bachelot, A. Penfornis, and M. Schlumberger Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma Ann. Onc., November 1, 2002; 13(11): 1806 - 1809. [Abstract] [Full Text] [PDF]

				D. C. MacGillivray, G. F. Whalen, C. D. Malchoff, D. S. Oppenheim, and S. J. Shichman Laparoscopic Resection of Large Adrenal Tumors Ann. Surg. Oncol., June 1, 2002; 9(5): 480 - 485. [Abstract] [Full Text] [PDF]

				A. Stojadinovic, R. A. Ghossein, A. Hoos, A. Nissan, D. Marshall, M. Dudas, C. Cordon-Cardo, D. P. Jaques, and M. F. Brennan Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization J. Clin. Oncol., February 15, 2002; 20(4): 941 - 950. [Abstract] [Full Text] [PDF]

				M. L. Kendrick, R. Lloyd, L. Erickson, D. R. Farley, C. S. Grant, G. B. Thompson, C. Rowland, W. F. Young Jr, and J. A. van Heerden Adrenocortical Carcinoma: Surgical Progress or Status Quo? Arch Surg, May 1, 2001; 136(5): 543 - 549. [Abstract] [Full Text] [PDF]